Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in relapsed/refractory CLL after BCR inhibitor therapy
NCT02141282Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2014
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in chronic lymphocytic leukemia (CLL), sponsored by AbbVie Inc.. Started Sep 2014; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02141282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141282.